Biogen sues Bayer, Pfizer for MS royalties; J&J's Velcade gets first-line NICE nod;

@FiercePharma: Novo leads revolt against Greek price cuts. Article | Follow @FiercePharma

> Biogen Idec has sued Bayer, Pfizer, and Merck KGaA's Serono unit for patent royalties on multiple sclerosis drugs similar to its Avonex treatment. Report

> Britain's cost-effectiveness watchdog NICE recommended Johnson & Johnson's drug Velcade as a first-line treatment for multiple myeloma in draft guidance; currently, it is recommended for second-line use. Report

> Guggenheim Partners offered to buy Sun Pharmaceutical Industries' stake in Taro Pharmaceuticals on behalf of clients for about $215 million. Report

> Novo Nordisk, the world's biggest maker of diabetes care products, plans to launch its potential blockbuster drug Victoza in Japan this month. Report

> Danish drugmaker H. Lundbeck's business in France is expected to grow by a double-digit percentage this year and next, its French operations director said. Report

> Jeffries International upgraded GlaxoSmithKline to "buy" from "hold," citing its expectations for "a period of more sustainable earnings growth from longer-duration assets." Report

> Contract manufacturers are set to gain biologics business and capacity in the coming years as large pharma increasingly outsources to cut costs and speed development, according to a new report. Report

Biotech News

 @FierceBiotech: Researcher: New vaccine "could eliminate breast cancer." Story | Follow @FierceBiotech

 @JohnCFierce: Bit dated, but this New York Times piece on dangers in the lab seems a bit inflated with anecdotes and seriously short on facts. Report | Follow @JohnCFierce

> Constellation banks $22M for ambitious epigenetics play. Story

> Theratechnologies' Yves Rosconi to retire. Item

> Orexo inks $585M drug pact with J&J. Report

> Boom spurs India's biotech industry to hatch expansion plans. Article

> Amgen wins FDA approval of D-mab. News

Drug Delivery News

 

> Elan stays focused on drug technology spin-off. Article

> Nanoparticle delivery system used to defeat ebola virus. Report

> Researchers attack cancer with sustained siRNA delivery. News

> NanoViricides anti-Dengue drugs effective in new study. Report

> Gold nanorods may thwart pandemics. Item

Medical Devices News

> Elekta forks over $28.5M for Resonant Medical. Story

> Medtronic discloses $15.7M in physician payments. News

> GenMark IPO price range lowered. Item

> Altura Medical lands $20M in VC. Report

And Finally... Taking common antidepressants while pregnant significantly increases the chances of suffering a miscarriage, a new study warns. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.